Our plants are operated under the global standards and fully equipped with the modernized system, one of the best production facilities for pharmaceuticals in Korea. We also run CMO business under stringent quality system.
Osong plant is Korea’s top-notch pharmaceutical manufacturing facilities where high-quality oral solid dosage forms and oncology injectables are manufactured.
Address | 239, Osongsaengmyeong 2-ro, Mansu-ri, Osong-eup, Heungdeok-gu, Cheongju-si, Chungcheongbuk-do 28158, Republic of Korea |
---|---|
Site area | 146,013 m² |
Building area | 25,184.5 m² |
Manufacturing Facilities | Oral Solid Dosage Forms, Cytotoxic Oncology Injectables, Automated Warehouse, QC/QA Building, etc. |
Major dosage forms | Oral solid dosage forms, Oncology injectables |
Oral Solid Dosage Forms
Closed system Closed system for manufacturing high-quality products
capable of manufacturing products in various scales
• Three identical granulation lines with 30/100/300 Kg capacities
• 2 billion tablets and 1 billion capsules per year
The oral solid dosage form site is designed to minimize mix-up between processes from warehouse to the final production step. All products are manufactured in a completely sealed condition by using the BIN system in order to eliminate external and cross contamination. In addition, various-scaled production is possible with establishment of the 30/100/300kg granule lines. The modern production equipment of the Osong plant for production of high-quality tablets/capsules is being utilized as infrastructure for product development, clinical sample, and commercial product manufacturing. All facilities are operated under the automatic computerized predefined system meeting 21 CFR Part 11.
Cytotoxic Oncology Injectables
Dedicated site for cytotoxic oncology products
Secured from external contamination by operating closed system
• Building dedicated to the cytotoxic injectables
• Closed Restricted Access Barrier System technology
The separate Cytotoxic injectables facility handles all of manufacturing processes including
manufacturing, storage, packaging, and quality control. It has been designed to perfectly respond to the increasingly toughened global regulations.
The Cytotoxic injectables facility is characterized by not only the separate water/HVAC system but also the state-of-the-art facilities including the prescription department featuring automatic CIP/SIP, the isolators for weighing, the aseptic transfer system, and the filling & capping machines adopting the cRABS(closed Restricted Access Barrier System) technology.
All the processes are operated under a perfectly closed system to prevent from external contamination during the manufacturing of cytotoxic injectables and to ensure safe environment for workers.